Related Experiment Video
Updated: Jan 30, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Action plan for optimizing the design of clinical trials in chronic kidney disease
Vlado Perkovic1, Jonathan C Craig2,3, Worawon Chailimpamontree4
1The George Institute for Global Health, University of New South Wales Sydney, New South Wales, Australia.
Abstract:
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
More Related Videos
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

